Answers are grounded in this paper and cite their sources.
This review highlights the beneficial effects and explores the potential mechanisms of RAS blockade in preventing myocardial ischemia/reperfusion injury and adverse remodeling following myocardial infarction.
Experimental and clinical studies have demonstrated that myocardial ischemia induces activation of various components of the renin-angiotensin system (RAS), including angiotensinogen, renin, angiotensin-converting enzyme (ACE), angiotensins, and angiotensin receptors, in the acute phase of myocardial infarction and the postinfarction remodeling process. Pharmacological inhibition of the RAS by administration of renin inhibitors, ACE inhibitors, and angiotensin receptor blockers has shown beneficial effects on the pathological processes of myocardial infarction in both experimental animal studies and clinical trials. However, the potential mechanisms responsible for the cardioprotection of RAS inhibition remain unclear. In this review, we discuss roles of RAS blocking in the prevention of myocardial ischemia/reperfusion injury and postinfarction remodeling.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: